A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine

(2012) Masanori Noguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

(2011) Yingzi Ge et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature

(2011) T. Nelius et al.   CANCER TREATMENT REVIEWS

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

(2010) Masanori Noguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

(2010) Tetsuro Sasada et al.   EUROPEAN JOURNAL OF CANCER

A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer

(2010) Masanori Noguchi et al.   PROSTATE

METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER

(2009) O.Graciela Scharovsky et al.   Current Oncology

Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation

(2009) Leisha A. Emens et al.   JOURNAL OF CLINICAL ONCOLOGY

CD8+CD28− cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients

(2009) Bülent Karagöz et al.   MEDICAL ONCOLOGY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells

(2008) P. Serafini et al.   CANCER RESEARCH

Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

(2008) K. S. Sfanos et al.   CLINICAL CANCER RESEARCH